Patents by Inventor Motoo Yamasaki
Motoo Yamasaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230142095Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: ApplicationFiled: October 4, 2022Publication date: May 11, 2023Applicant: University of MiyazakiInventors: Kazuo Kitamura, Motoo Yamasaki
-
Patent number: 11578112Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. An aspect of the invention relates to a compound represented by formula (I): [wherein A is an Fc region of an immunoglobulin, B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, and L is a linking group comprising a peptide having any given amino acid sequence] or a salt thereof, or a hydrate thereof. Another aspect of the invention relates to a method for producing the compound represented by formula (I), and a medicament comprising the compound as an active ingredient. A-L-B??(I).Type: GrantFiled: March 29, 2018Date of Patent: February 14, 2023Assignee: University of MiyazakiInventors: Kazuo Kitamura, Motoo Yamasaki, Sayaka Nagata
-
Patent number: 11478551Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2-B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: GrantFiled: September 29, 2020Date of Patent: October 25, 2022Assignee: University of MiyazakiInventors: Kazuo Kitamura, Motoo Yamasaki
-
Publication number: 20210115103Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. An aspect of the invention relates to a compound represented by formula (I): [wherein A is an Fc region of an immunoglobulin, B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, and L is a linking group comprising a peptide having any given amino acid sequence] or a salt thereof, or a hydrate thereof. Another aspect of the invention relates to a method for producing the compound represented by formula (I), and a medicament comprising the compound as an active ingredient.Type: ApplicationFiled: March 29, 2018Publication date: April 22, 2021Applicant: UNIVERSITY OF MIYAZAKIInventors: Kazuo KITAMURA, Motoo YAMASAKI, Sayaka NAGATA
-
Publication number: 20210008219Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2-B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: ApplicationFiled: September 29, 2020Publication date: January 14, 2021Applicant: University of MiyazakiInventors: Kazuo Kitamura, Motoo Yamasaki
-
Patent number: 10842879Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: GrantFiled: September 16, 2016Date of Patent: November 24, 2020Assignee: UNIVERSITY OF MIYAZAKIInventors: Kazuo Kitamura, Motoo Yamasaki
-
Publication number: 20200017593Abstract: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.Type: ApplicationFiled: July 22, 2019Publication date: January 16, 2020Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Nobuo HANAI, Kazuyasu NAKAMURA, Emi HOSAKA, Motoo YAMASAKI, Kazuhisa UCHIDA, Toyohide SHINKAWA, Susumu IMABEPPU, Yutaka KANDA, Naoko YAMANE, Hideharu ANAZAWA
-
Publication number: 20190360015Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: ApplicationFiled: January 29, 2019Publication date: November 28, 2019Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
-
Patent number: 10233475Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: GrantFiled: July 5, 2016Date of Patent: March 19, 2019Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
-
Patent number: 10233246Abstract: The present invention relates to an antibody or antibody fragment comprising novel Cys residue, to which a hydrophilic macromolecular group or amphipathic macromolecular group can be bound at a high efficiency. In addition, the present invention relates to a monoclonal antibody modified product or an antibody fragment modified product in which cysteine residue is chemically modified.Type: GrantFiled: August 19, 2015Date of Patent: March 19, 2019Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Motoo Yamasaki, Yasuhisa Shiraishi
-
Patent number: 10233247Abstract: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.Type: GrantFiled: February 5, 2014Date of Patent: March 19, 2019Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Nobuo Hanai, Kazuyasu Nakamura, Emi Hosaka, Motoo Yamasaki, Kazuhisa Uchida, Toyohide Shinkawa, Susumu Imabeppu, Yutaka Kanda, Naoko Yamane, Hideharu Anazawa
-
Publication number: 20180264123Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: ApplicationFiled: September 16, 2016Publication date: September 20, 2018Applicant: University of MiyazakiInventors: Kazuo Kitamura, Motoo Yamasaki
-
Publication number: 20170240647Abstract: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.Type: ApplicationFiled: March 16, 2017Publication date: August 24, 2017Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Nobuo HANAI, Kazuyasu NAKAMURA, Emi HOSAKA, Motoo YAMASAKI, Kazuhisa UCHIDA, Toyohide SHINKAWA, Susumu IMABEPPU, Yutaka KANDA, Naoko YAMANE, Hideharu ANAZAWA
-
Patent number: 9637545Abstract: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.Type: GrantFiled: February 5, 2014Date of Patent: May 2, 2017Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Nobuo Hanai, Kazuyasu Nakamura, Emi Hosaka, Motoo Yamasaki, Kazuhisa Uchida, Toyohide Shinkawa, Susumu Imabeppu, Yutaka Kanda, Naoko Yamane, Hideharu Anazawa
-
Publication number: 20160348145Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: ApplicationFiled: July 5, 2016Publication date: December 1, 2016Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Yutaka KANDA, Mitsuo SATOH, Kazuyasu NAKAMURA, Kazuhisa UCHIDA, Toyohide SHINKAWA, Naoko YAMANE, Emi HOSAKA, Kazuya YAMANO, Motoo YAMASAKI, Nobuo HANAI
-
Patent number: 9409982Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependant cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: GrantFiled: October 22, 2014Date of Patent: August 9, 2016Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
-
Publication number: 20160039937Abstract: The present invention relates to an antibody or antibody fragment comprising novel Cys residue, to which a hydrophilic macromolecular group or amphipathic macromolecular group can be bound at a high efficiency. In addition, the present invention relates to a monoclonal antibody modified product or an antibody fragment modified product in which cysteine residue is chemically modified.Type: ApplicationFiled: August 19, 2015Publication date: February 11, 2016Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Motoo YAMASAKI, Yasuhisa SHIRAISHI
-
Patent number: 9150639Abstract: The present invention relates to an antibody or antibody fragment comprising novel Cys residue, to which a hydrophilic macromolecular group or amphipathic macromolecular group can be bound at a high efficiency. In addition, the present invention relates to a monoclonal antibody modified product or an antibody fragment modified product in which cysteine residue is chemically modified.Type: GrantFiled: March 28, 2011Date of Patent: October 6, 2015Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Motoo Yamasaki, Yasuhisa Shiraishi
-
Publication number: 20150112046Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependant cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: ApplicationFiled: October 22, 2014Publication date: April 23, 2015Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Yutaka KANDA, Mitsuo SATOH, Kazuyasu NAKAMURA, Kazuhisa UCHIDA, Toyohide SHINKAWA, Naoko YAMANE, Emi HOSAKA, Kazuya YAMANO, Motoo YAMASAKI, Nobuo HANAI
-
Patent number: 8895266Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.Type: GrantFiled: November 8, 2012Date of Patent: November 25, 2014Assignee: Kyowa Hakko Kirin Co., LtdInventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai